Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-26T13:04:36.925Z Has data issue: false hasContentIssue false
  • English
  • Français

Venlafaxine precipitated visual hallucinations

Published online by Cambridge University Press:  13 June 2014

Rafael A Gafoor
Rafael A Gafoor*
Affiliation:
Department of Psychiatry, Beaumont Hospital, Dublin 9, Ireland
Get access Rights & Permissions [Opens in a new window]

Abstract

A case of venlafaxine associated visual hallucinations is described. The underlying neurochemical pathophysiology is explored and recommendations for management of patients who experience this side effect are discussed.

Keywords

VenlafaxineHallucinationsSNRI
Type
Case Reports
Information
Irish Journal of Psychological Medicine , Volume 19 , Issue 3 , September 2002 , pp. 98 - 99
Copyright
Copyright © Cambridge University Press 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Klysner, R, Larsen, JK, Sorensen, P, Hyllestred, M, Poderson BD. Toxic interaction of venlafaxine and isocarboxazide. The Lancet 1995; 346: 1298–99.CrossRefGoogle Scholar
2.Anghelescu, Iet al.Topiramate in venlafaxine-induced visual hallucinations in an obese patient with a posterior cerebral artery infarction. J Clin Psychopharm 2001; 21 (4): 462–4.CrossRefGoogle Scholar
3.Parker, G, Blennerhassett, J. Withdrawal reactions associated with venlafaxine. Aust NZ J Psychiatry 1998; 32(2): 291–4.CrossRefGoogle ScholarPubMed
4.Frazer, A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 2001; 62: Suppl 12:16–23.Google ScholarPubMed
5.Millan, MJet al.S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 2001; 298(2): 581–91.Google ScholarPubMed
6.Aghajanian, GK, Marek, GJ. Serotonin and hallucinogens. Neuropsychopharmacology 1999; 21 (Suppl 2):16S–23S.CrossRefGoogle ScholarPubMed
7.Meltzer, HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21 (Suppl 2):106S–115S.CrossRefGoogle ScholarPubMed
8.Jones, Het al.Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. Am J Psychiatry 1998; 155(6): 838–40.Google ScholarPubMed
9.Meyer, JHet al.The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F] setoperone PET imaging study. Am J Psychiatry 2000; 158(1): 78–85.CrossRefGoogle Scholar
10.Bourgeois, JAet al.Visual hallucinations associated with fluoxetine and sertraline. J Clin Psychopharmacol 1998; 18(6): 482–3.CrossRefGoogle ScholarPubMed
11.Beique, JCet al.Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 1998; 349(1): 129–32.CrossRefGoogle ScholarPubMed